Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mediators that were identified support existing and novel hypothesized mechanisms for the prevention of heart failure with sodium glucose cotransporter 2 inhibitors.
|
31676303 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Robust data from stable outpatient cohorts indicate that the SGLT2 inhibitors are associated with clinically meaningful reductions in major adverse cardiovascular events, lower rates of hospitalization for heart failure, and a reduction in major kidney outcomes There is however a lack of information on how to initiate and manage SGLT2 inhibitors in an acute in-patient setting.
|
31804229 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unraveling the mechanisms behind the beneficial actions of SGLT2 inhibitors may not only contribute to a better understanding of the pathophysiology of cardiovascular diseases but also enable repurposing of gliflozins to improve the routine management of HF patients with or without T2D.
|
31721613 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve cardiovascular outcomes including hospitalization for heart failure and mortality in people with and without diabetes.<sup>1, 2</sup> The mechanism(s) underlying this benefit remain unclear.
|
31707794 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Emerging data have demonstrated that sodium-glucose cotransporter-2 (SGLT2) inhibitors prevent cardiovascular events, especially heart failure-associated endpoints.
|
31725011 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure.
|
31821814 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, the benefit of SGLT-2 inhibitors in a population of patients with HF yet without diabetes remains to be demonstrated across multiple trials.
|
31630988 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Empagliflozin, an SGLT2 inhibitor, has shown remarkable reductions in cardiovascular mortality and heart failure admissions (EMPA-REG OUTCOME).
|
31837891 |
2020 |
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Traditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents.<sup>1</sup> Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular (CV) events, including CV death, myocardial infarction (MI) and heart failure, and slow progression of renal dysfunction, including prevention of end-stage kidney disease (ESKD).<sup>2-3</sup> Because initial clinical trials included mostly patients with baseline HbA1c >7%, current guidelines have recommended this class as add-on therapy for patients whose HbA1c is not at goal, typically ≥7%.<sup>1</sup> We hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with HbA1c <7%.
|
31707795 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Accordingly, SGLT-2 inhibitors could be recommended to prevent HF hospitalisation in patients with T2DM and established cardiovascular disease or with multiple risk factors.
|
31816162 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using data from the US Get With The Guidelines (GWTG)-Heart Failure registry, we evaluated the proportion of patients with DM and HF eligible for SGLT-2 inhibitor therapy based on the clinical trial criteria and the US FDA labelling criteria.
|
31747132 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amongst those with type 2 diabetes mellitus who did not have established cardiovascular disease but did present with multiple risk factors, SGLT2 inhibitors lowered the combined endpoint of cardiovascular death or hospitalization for heart failure but had little impact on the occurrence of major adverse cardiac events.
|
31839265 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were no differences in the risk ratios between men and women, SGLT2 versus control (placebo), for vascular efficacy outcomes or death (all P for interaction ≥.12), with clear protection shown against major adverse cardiovascular events, heart failure, vascular death and total mortality.
|
31486272 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that SGLT2 inhibitors may be novel therapeutics against reduced exercise endurance capacity in HF, by improving mitochondrial fatty acid oxidation in skeletal muscle.
|
31738936 |
2020 |
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ongoing clinical trials will uncover the potential benefit of SGLT2 inhibitors in patients with prevalent heart failure with or without diabetes mellitus.
|
31494110 |
2020 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes.
|
31584231 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are drugs for diabetes and might prevent heart failure.
|
31105148 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: DECLARE-TIMI 58 is the longest (4.2 years of follow up), largest (>17,000 participants) and most inclusive (only 41% of individuals with established atherosclerotic cardiovascular disease) CVOT raising the debate towards SGLT2 inhibitor therapy in primary prevention and the potential use of these drugs also in patients with HF without T2DM and other subpopulations.
|
30920851 |
2019 |
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While little is yet known about SGLT subtype 1, SGLT2 inhibitors have demonstrated to significantly reduce cardiovascular mortality and heart failure hospitalizations.
|
31277431 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D).
|
31440988 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
While dipeptidyl peptidase-4 (DPP-4) inhibitors exhibited increased heart failure hospitalization in the SAVOR-TIMI 53 trial evaluating saxagliptin and in the secondary analysis of the EXAMINE trial for alogliptin, the effects of glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose co-transporter-2 (SGLT2) inhibitors on CV outcomes in diabetes have largely been positive.
|
30767126 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SGLT-2 inhibitors have opened a new perspective for clinicians treating patients with T2D and established CV disease in light of their 'pleiotropic' effects, specifically on heart failure, while GLP-1RAs seem to present more favourable effects on atherosclerotic events.
|
30888088 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, the DECLARE-TIMI 58 study (of dapagliflozin) clearly indicates strong protection for heart failure in those with CVD, and probably in those with no prior CVD.
|
30607467 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, novel drugs that have received interest in HF include angiotensin receptor blocker-neprilysin inhibitor (ARNi) and sodium glucose cotransporter 2 (SGLT-2) inhibitors, whose favorable cardiovascular profile has been at least partly attributed to their effects on metabolism.
|
30149104 |
2019 |
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the available evidence, we conclude that SGLT-2 inhibitors represent an evidence-based therapeutic option for the primary prevention of heart failure hospitalization and secondary prevention of CVD in patients with T2DM, and should be considered early on in the treatment algorithm for patients with multiple risk factors, or those with established CVD.
|
31264765 |
2019 |